No­var­tis paus­es en­roll­ment for Kisqali breast can­cer tri­als to align with ni­trosamine guide­lines

No­var­tis is tem­porar­i­ly stop­ping en­roll­ment of ear­ly breast can­cer pa­tients in­to clin­i­cal tri­als for Kisqali as it ad­justs to new reg­u­la­to­ry guid­ance on lim­its for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER